Home » Markets » House committee to subpoena Humira maker in investigation of arthritis drug pricing
Comments Off on House committee to subpoena Humira maker in investigation of arthritis drug pricingMarkets
House committee to subpoena Humira maker in investigation of arthritis drug pricing
AbbVie buying Allergan in deal valued at $63B
Benchmark Managing Partner Kevin Kelly on AbbVie buying Allergan in a cash and stock deal valued at $63 billion.
The House Committee on Oversight and Reform on Tuesday said it will subpoena biopharmaceutical company AbbVie Inc. in its investigation of the company's drug-pricing practices.
Continue Reading Below
The committee will be looking at AbbVie's pricing practices for its Humira arthritis drug, which made a revenue of more than $19.2 billion in 2019, as well as its Imbruvica mantle cell lymphoma treatment, which made a revenue of more than $4.6 billion in 2019, according to a press release.
BIG PHARMA PUSHES BACK ON TRUMP DRUG PRICING PLAN, PFIZER SAID IT COULD CUT US JOBS
The late Rep. Elijah E. Cummings, D-Md., initiated the investigation into AbbVie and 11 other companies for their drug pricing practices in January of 2019.
Cummings sent three letters to AbbVie CEO Richard Gonzalez before October of 2019 requesting the company to comply with the committee's demands for information.
HUMIRA TO BE OVERTHROWN AS WORLD'S TOP-SELLING DRUG, REPORT PREDICTS
"After more than 18 months, AbbVie has demonstrated its unwillingness to comply voluntarily with the Committee's investigation," Committee Chairwoman Rep. Carolyn Maloney, D-NY, wrote in a memorandum to committee members Tuesday.